The role of miRNAs in the pathogenesis, diagnosis, and treatment of colorectal cancer and colitis-associated cancer DOI Creative Commons
Marcin Włodarczyk, Kasper Maryńczak,

Jacek Burzyński

et al.

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 16, 2025

MicroRNAs (miRNAs) are a group of noncoding single-stranded RNA biomolecules that act in posttranscriptional regulation gene expression. Their role the development inflammatory bowel disease (IBD), colitis-associated cancer (CAC), and colorectal (CRC) is currently under investigation. A few miRNAs present promising results terms diagnostic or therapeutic use, for example, miR-21 increases CRC inflammation, while also being possible target therapy; miR-301a inflammation but only patients with IBD; miR-31 CRC, especially advanced stages, namely III-IV TNM scale; miR-200 family plays carcinogenesis other tumors; examined as group, miR-31-5p, miR-223-3p, let-7f-5p trigger exacerbate CAC; miR-19a could potentially be used therapy prevention both CAC. Here, we discuss available studies outline future directions concerning validity using diagnosis and/or IBD, CAC, CRC. Extensive research confirms play an important pathogenesis CAC Since significantly altered expression certain early prognostic marker these diseases, have potential to serve tools, enabling quick straightforward detection.

Language: Английский

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis DOI Creative Commons
Deniz Can Güven, Taha Koray Şahin, Enes Erul

et al.

Frontiers in Molecular Biosciences, Journal Year: 2022, Volume and Issue: 9

Published: Dec. 2, 2022

Background: The albumin levels may potentially be used as a prognostic biomarker in patients with cancertreated immune checkpoint inhibitors (ICIs) due to its close relationship nutritional and inflammatory status. However, the available data is limited heterogeneous patient cohorts, sample sizes variable cut-offs. Therefore, we conducted systematic review meta-analysis evaluate association between survival outcomes treated ICIs. Methods: We using PubMed, Web of Science, Embase databases filter published studies up 1 June 2022. meta-analyses were performed generic inverse-variance method random-effects model high degree heterogeneity. primary outcome measure was hazard ratio (HR) 95% confidence intervals (CI). study protocol registered PROSPERO registry (Registration Number: CRD42022337746). Results: Thirty-six encompassing 8406 cancer advanced disease included meta-analyses. Almost half NSCLC cohorts (n = 15), 3.5 gr/dL most frequently cut-off 20). Patients lower had significantly increased risk death (HR: 1.65, CI: 1.52–1.80, p < 0.0001) than higher levels. Subgroup analyses for location, size, tumor type demonstrated consistent results. Furthermore, subgroup analysis eight continuous factor, every decrease associated by factor 10% 1.10, 1.05–1.16, 0.0002). Similar overall survival, an progression or compared 1.76, 1.40–2.21, 0.001). Conclusion: evidence demonstrates that Further research needed delineate role ICIs adjuvant setting, well possible benefit therapeutic approaches improve hypoalbuminemia.

Language: Английский

Citations

133
Calculus bovis inhibits M2 tumor-associated macrophage polarization via Wnt/β-catenin pathway modulation to suppress liver cancer DOI
Zhen Huang, Fanying Meng,

Lin-Zhu Lu

et al.

World Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 30(29), P. 3511 - 3533

Published: July 28, 2024

(CB), used in traditional Chinese medicine, exhibits anti-tumor effects various cancer models. It also constitutes an integral component of a compound formulation known as Pien Tze Huang, which is indicated for the treatment liver cancer. However, its impact on tumor microenvironment, particularly tumor-associated macrophages (TAMs), not well understood.

Language: Английский

Citations

22
Polymeric nanoparticles as delivery vehicles for targeted delivery of chemotherapy drug fludarabine to treat hematological cancers DOI

Mehrab Pourmadadi,

Hamed Mirzaei Dehaghi,

Amirhossein Ghaemi

et al.

Inorganic Chemistry Communications, Journal Year: 2024, Volume and Issue: 167, P. 112819 - 112819

Published: July 6, 2024

Language: Английский

Citations

11
Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy DOI
Taha Koray Şahin, Yakup Özbay, Ahmet Yasir Altunbulak

et al.

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(6), P. 822 - 831

Published: April 2, 2024

Language: Английский

Citations

8
Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy DOI
Lingzhi Wang, Shengnan Bi, Zhuo Li

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 313, P. 122766 - 122766

Published: Aug. 22, 2024

Language: Английский

Citations

8
The association between HALP score and survival in patients treated with immune checkpoint inhibitors DOI
Taha Koray Şahin, Deniz Can Güven, Mine Durukan

et al.

Expert Review of Anticancer Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 9

Published: Jan. 7, 2025

Background The hemoglobin, albumin, lymphocyte, and platelet (HALP) score could be a prognostic biomarker in patients with cancer as reflector of nutritional inflammatory status, although the data is limited treated immune-checkpoint inhibitors (ICIs). Therefore, we sought to investigate relationship between HALP survival ICI-treated patients.

Language: Английский

Citations

1
Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancer DOI Creative Commons

Feiquan Ying,

Xuyang Zhou,

Mengqing Chen

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 33(1), P. 200938 - 200938

Published: Jan. 18, 2025

Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy. Precision treatments are crucial for improving patient survival. This research explored potential anti-tumor effects of combining inetetamab and atezolizumab HER2+ EOC patients. The expressions human epidermal growth factor receptor 2 (HER2) programmed cell death ligand 1 (PD-L1) in cells were evaluated. cell-derived subcutaneous peritoneal dissemination mouse models used to evaluate inetetamab, with or without atezolizumab. correlations between HER2 PD-L1 as well infiltration T tumors from patients mice analyzed by immunohistochemistry. Inetetamab suppressed models. overexpression increased levels cells. expression level positively related that both CD4+ CD8+ combination impeded vivo induced a long-term effect elevated CD103+CD8+ These findings suggest could be promising precision treatment strategy

Language: Английский

Citations

1
Efficacy and safety of different drugs in patients with HER2-positive gastric cancer: network meta-analysis DOI Creative Commons
Jie Zhang, Chunluan Yuan, Xiao Ma

et al.

Systematic Reviews, Journal Year: 2025, Volume and Issue: 14(1)

Published: Feb. 10, 2025

In the past decade, there has been a significant advancement in targeted therapy and immunotherapy, leading to discovery of new drugs changes treatment approach for patients with HER2-positive gastric cancer. Although several are available treating these patients, is still no consensus on their selection, limited direct or indirect comparison among them. To address this gap, network meta-analysis was conducted assess efficacy safety different used By searching through databases such as PubMed, Embase, Web Science, Cochrane Library, we identified 16 randomized controlled trials that involved total 4485 utilized 9 intervention measures. Based current evidence, compared chemotherapy alone, hazard ratio (HR) overall survival (OS) progression-free (PFS) cancer treated nivolumab were [hazard (HR): 2.61 95%confidence interval (CI) (1.51, 4.51)] 2.01 95% confidence (1.18, 3.42)], respectively. Compared trastuzumab deruxtecan 1.7 (1.13, 2.56)] 2.13 (1.42, 3.22)], It suggested can effectively prolong survival(PFS) cancer, while also reducing risk adverse events some extent. Therefore, two regimens, deruxtecan, considered be effective safe options previous studies, trastuzumab-based common certain extent, our study provides reliable direction future PROSPERO CRD42023420941

Language: Английский

Citations

1
The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy DOI Creative Commons

Sajjad Ahmadpour,

Mohammad Amin Habibi,

Farzaneh Sadat Ghazi

et al.

Cancer Treatment and Research Communications, Journal Year: 2024, Volume and Issue: 40, P. 100823 - 100823

Published: Jan. 1, 2024

Tumors can produce bioactive substances called tumor-derived supernatants (TDS) that modify the immune response in host body. This result immunosuppressive effects promote growth and spread of cancer. During tumorigenesis, exudation these disrupt function sentinels reinforce support for cancer cell growth. Tumor cells cytokines, factors, proteins, which contribute to progression tumor formation premetastatic niches. By understanding how influence system through secretion we gain new insights into diagnosis therapy.

Language: Английский

Citations

6
Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma DOI Creative Commons
Di Wu, Yibing Liu, Jianjun Liu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 29, 2024

Considering the key role of myeloid cell differentiation—related genes in tumor microenvironment (TME), we aimed to build a prognostic risk model using these for Lung adenocarcinoma (LUAD). The mRNA gene expression profiles LUAD patients from Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were downloaded as training validation sets. Then, "edgeR" R package was applied screen out differentially expressed (DEGs) univariate cox regression, backward stepwise selection analyses performed construct LUAD. ESTIMATE, TIMER, XCELL, CIBERSORT abs, QUANTISEQ, MCPCOUNTER, EPIC, algorithms conducted access association levels with stromal immune infiltration Six (F2RL1, PRKDC, TNFSF11, INHA, PLA2G3 TUBB1) utilized model. showed excellent performance both TCGA GEO datasets. Also, compared low-risk patients, high-risk had higher checkpoint molecules lower IC50 value chemotherapy agents. Our findings provided signature that could effectively predict prognosis guide treatment strategies patients.

Language: Английский

Citations

5